Brought to you by:
Artificial intelligence could make endovascular aortic repair outcomes more predictable, CX 2022 hears
At the 2022 Charing Cross (CX) International Symposium (April 26–28) in London, England, Tom Carrell, MD, a vascular surgeon in Cambridge, England, and founder of Cydar Medical, delivered a Podium 1st presentation titled “Making endovascular aortic repair outcomes more predictable: Artificial…
SCAI releases multi-society position statement focused on core competencies for endovascular specialists providing care for CLTI
The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement outlining competencies for endovascular specialists who provide care for chronic limb-threatening ischemia (CLTI). The first-of-its-kind document, “SCAI/ACR/APMA/SCVS/SIR/SVM/SVS/VESS position statement on competencies for endovascular specialists providing CLTI care,”…
Voting for SVS vice president, secretary begins May 23
Society for Vascular Surgery (SVS) Active and Senior members will begin voting May 23 for a new SVS vice president and secretary for 2022–23. Election results will be announced at the SVS Annual Business Meeting on June 18 during the…
New sirolimus data provide encouragement despite ‘potentially disappointing’ efficacy results
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access for dialysis. These findings were delivered by Tjun Tang, MD—who also highlighted “excellent” technical and clinical…
FDA approves expanded indications for TCAR’s Enroute stent
The Food and Drug Administration (FDA) approved expanded indications for the Enroute stent system—part of the transcarotid artery revascularization (TCAR) procedure—to include patients at standard risk for adverse events from carotid endarterectomy (CEA), Silk Road Medical announced today. Previously, the…
SVS Foundation seeks applicants for VISTA projects
The SVS Foundation started to seek proposals in mid-April for pilot outreach projects to help identify needed vascular services in underserved portions of the U.S. The projects will be part of the Foundation’s VISTA (Vascular Volunteers In Service To All)…
CX 2022: IN.PACT AV DCB shows sustained and superior performance compared to PTA through three years
New randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug-coated balloons (DCBs) compared to percutaneous transluminal angioplasty (PTA) through 36 months, with no difference in mortality, was revealed during a Podium 1st presentation at the 2022 Charing…
SVS turns its sights to FY2023, long-range future
In January, the Society for Vascular Surgery (SVS) Strategic Board met and forged its objectives for the coming fiscal year. Two months later the course is being set for action as goals translate into objectives, and objectives transform into programs…
CX 2022: Overtreatment in venous disease: Financial incentives are ‘the elephant in the room’
To combat the “overtreatment problem” in the appropriate care of venous disease, “a concerted, complex, multimodal effort” is required from specialists across disparate parts of the world. That was the conclusion delivered by Manj Gohel, MD, of Cambridge University Hospitals,…
SVS members receive deep discount on key textbooks
Society for Vascular Surgery (SVS) members receive many important discounts as a privilege of belonging. These perks include discounts to important references in diagnosing and treating vascular injury, including Rich’s Vascular Trauma and Rutherford’s Vascular Surgery and Endovascular Therapy. Both…